New drug candidate slows the progression of adrenoleukodystrophy

The work of Professor Fanny Mochel (AP-HP, Sorbonne University) at Paris Brain Institute, in collaboration with clinical research teams in eight countries and Spanish biotech Minoryx Therapeutics, has demonstrated the protective effects of leriglitazone in the progression of adrenoleukodystrophy—a rare genetic disease in which the white matter of the central nervous system is damaged. The results are published in The Lancet Neurology.